Focus: CMP Pharma is a small-molecule pharmaceutical manufacturer founded in 1975, headquartered in Farmville, NC, with a portfolio focused on nephrology, immunology, and infectious disease generics.
Profile data last refreshed 5h ago · AI intelligence enriched 3w ago
CMP Pharma is a stable, mature generics operator suited for commercial and operations professionals seeking steady-state pharmaceutical manufacturing roles, but offers limited R&D career growth or pipeline upside.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Potassium ion exchange resin for nephrology; post-exclusivity generics compete on cost and supply.
Help build intelligence for CMP Pharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from CMP Pharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
First-line anti-TB agent; bactericidal mechanism via mycoloic acid inhibition; established infectious disease standard.
Intranasal corticosteroid for adults and children ≥12 years; competitive generics market with stable demand.
Duplicate potassium management indication; underscores portfolio concentration risk in nephrology segment.
Topical corticosteroid formulation; niche indication in immunology/inflammation with modest market size.
1 discontinued, 1 duplicate formulations not shown
Based on last 4 crawl cycles
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo